NCT02027961View on ClinicalTrials.gov

Phase 1 Safety and Tolerability of MEDI4736 in Combination With Dabrafenib and Trametinib or With Trametinib Alone

PHASE1CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

December 20, 2013

Primary Completion Date

April 24, 2018

Study Completion Date

April 24, 2018

Conditions
Melanoma
Interventions
BIOLOGICAL

Durvalumab

Intravenous dose of 3 or 10 mg/kg durvalumab.

DRUG

Dabrafenib

Oral dose of 150 mg dabrafenib capsule.

DRUG

Trametinib

Oral dose of 2 mg trametinib tablet.

Trial Locations (11)

33140

Research Site, Miami Beach

60611

Research Site, Chicago

63110

Research Site, St Louis

80131

Research Site, Napoli

85258

Research Site, Scottsdale

90095

Research Site, Los Angeles

94115

Research Site, San Francisco

94805

Research Site, Villejuif

02114

Research Site, Boston

M5G 2M9

Research Site, Toronto

H3A 1A1

Research Site, Montreal

Sponsors

Lead Sponsor

MedImmune LLC
All Listed Sponsors
lead

MedImmune LLC

INDUSTRY